Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Global Cancer/Tumour Profiling Market: By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Others; By Biomarker Type; By Technology; By Application; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics; Competitive Landscape; Industry Events and Developments
Global Cancer/Tumour Profiling Market Outlook
The global cancer/tumour profiling market attained a value of USD around 7.8 billion in 2020. The cancer/tumour profiling market is further expected to grow in the forecast period of 2022-2027 at a CAGR of 10.2% to reach USD 14 billion by 2026.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The rising rate of cancer globally and the growing use of biomarkers in the production of tumours are the main drivers for the growth of the cancer/tumour profiling market.
Market Segmentation
Cancer is a life-threatening illness that is characterised by uncontrolled cell growth. This is mainly due to environmental reasons which alter the gene encoding that regulates cells. The resulting cell mutation results in abnormal cell growth, killing the surrounding normal tissue and then spreading it to very important organs. Cancer/tumour profiling is done to gain insight into a patient's cancer profile and genomic adjustments that enable physicians to guide a patient to the most appropriate treatment. Therefore, profiling also allows doctors to avoid interventions that are questionable and, thus, reduce mistakes and trial procedures.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The types of cancer can be divided into:
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma
- Others
The types of biosensors can be segmented into:
- Genetic Biomarkers
- Protein Biomarkers
- Others
The cancer/tumour profiling market can be broadly categorised based on technology into:
- Immunoassays
- Next-Generation Sequencing
- Polymerase Chain Reaction
- In Situ Hybridization
- Microarrays
- Mass Spectrometry
- Others
It finds its uses in the research and clinical applications.
Research applications can be further divided into:
- Biomarker Discovery
- Personalized Medicine
Clinical applications are further categorised into:
- Diagnostics
- Prognostics
- Monitoring and Treatment
- Screening
The EMR report looks into the regional markets of cancer/tumour profiling like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
A significant growth in the global market for cancer/tumour profiling is expected in the coming years, mainly owing to the increased funding of activities to improve the overall course of the diagnosis and treatment of the disease and the recent comprehensive technological advancements in the area of tumour profiling. The market is also being driven by the growing use of medical diagnostics and the resulting increase in the demand for personalized medicinal products.
The constantly increasing socio-economic burden of cancer and the demand from the health industry to establish effective methods of treating and controlling it also drives the market for the profiling of cancer/tumours. Nonetheless, the additional expenditure needed by profiling procedures may in some way impede its adoption, limiting the scope of these processes to high-income regions. Nonetheless, through government intervention and support from the public and private institutions for cancer diagnosis and treatment are expected to allow the market to achieve promising avenues for development.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global cancer/tumour profiling market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Illumina, Inc. (NASDAQ: ILMN)
- Qiagen N.V.
- Neogenomic Laboratories, Inc.
- Sysmex Corporation
- HTG Molecular Diagnostics, Inc.
- Helomics Corporation
- Caris Life Sciences
- Others
The EMR report gives an in-depth insight into the cancer/tumour profiling market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2020 |
| Historical Period | 2017-2021 |
| Forecast Period | 2022-2027 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Cancer Type, Biomarker Type, Technology, Application, Region |
| Breakup by Cancer Type | Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Others |
| Breakup by Biomarker Type | Genetic Biomarkers, Protein Biomarkers, Others |
| Breakup by Technology | Immunoassays, Next-Generation Sequencing, Polymerase Chain Reaction, In Situ Hybridization, Microarrays, Mass Spectrometry, Others |
| Breakup by Application | Research Applications, Clinical Applications |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Illumina, Inc. (NASDAQ: ILMN), Qiagen N.V. (NYSE: QGEN), Neogenomic Laboratories, Inc. (NASDAQ: NEO), Sysmex Corporation (TYO: 6869), HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM), Helomics Corporation, Caris Life Sciences, Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Cancer/Tumour Profiling Market Analysis
8.1 Key Industry Highlights
8.2 Global Cancer/Tumour Profiling Historical Market (2017-2021)
8.3 Global Cancer/Tumour Profiling Market Forecast (2022-2027)
8.4 Global Cancer/Tumour Profiling Market by Cancer Type
8.4.1 Breast Cancer
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.2 Lung Cancer
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.4.3 Colorectal Cancer
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2017-2021)
8.4.3.3 Forecast Trend (2022-2027)
8.4.4 Prostate Cancer
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2017-2021)
8.4.4.3 Forecast Trend (2022-2027)
8.4.5 Melanoma
8.4.5.1 Market Share
8.4.5.2 Historical Trend (2017-2021)
8.4.5.3 Forecast Trend (2022-2027)
8.4.6 Others
8.5 Global Cancer/Tumour Profiling Market by Biomarker Type
8.5.1 Genetic Biomarkers
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2017-2021)
8.5.1.3 Forecast Trend (2022-2027)
8.5.2 Protein Biomarkers
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2017-2021)
8.5.2.3 Forecast Trend (2022-2027)
8.5.3 Others
8.6 Global Cancer/Tumour Profiling Market by Technology
8.6.1 Immunoassays
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2017-2021)
8.6.1.3 Forecast Trend (2022-2027)
8.6.2 Next-Generation Sequencing
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2017-2021)
8.6.2.3 Forecast Trend (2022-2027)
8.6.3 Polymerase Chain Reaction
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2017-2021)
8.6.3.3 Forecast Trend (2022-2027)
8.6.4 In Situ Hybridization
8.6.4.1 Market Share
8.6.4.2 Historical Trend (2017-2021)
8.6.4.3 Forecast Trend (2022-2027)
8.6.5 Microarrays
8.6.5.1 Market Share
8.6.5.2 Historical Trend (2017-2021)
8.6.5.3 Forecast Trend (2022-2027)
8.6.6 Mass Spectrometry
8.6.6.1 Market Share
8.6.6.2 Historical Trend (2017-2021)
8.6.6.3 Forecast Trend (2022-2027)
8.6.7 Others
8.7 Global Cancer/Tumour Profiling Market by Application
8.7.1 Research Applications
8.7.1.1 Market Share
8.7.1.2 Historical Trend (2017-2021)
8.7.1.3 Forecast Trend (2022-2027)
8.7.1.4 Breakup by Type
8.7.1.4.1 Biomarker Discovery
8.7.1.4.2 Personalised Medicine
8.7.2 Clinical Applications
8.7.2.1 Market Share
8.7.2.2 Historical Trend (2017-2021)
8.7.2.3 Forecast Trend (2022-2027)
8.7.2.4 Breakup by Type
8.7.2.4.1 Diagnostics
8.7.2.4.2 Prognostics
8.7.2.4.3 Monitoring and Treatment
8.7.2.4.4 Screening
8.8 Global Cancer/Tumour Profiling Market by Region
8.8.1 Market Share
8.8.1.1 North America
8.8.1.2 Europe
8.8.1.3 Asia Pacific
8.8.1.4 Latin America
8.8.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 Illumina, Inc.
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 Qiagen N.V.
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 NeoGenomics Laboratories, Inc.
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Sysmex Corporation
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 HTG Molecular Diagnostics, Inc.
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 Helomics Corporation
12.2.6.1 Company Overview
12.2.6.2 Product Portfolio
12.2.6.3 Demographic Reach and Achievements
12.2.6.4 Certifications
12.2.7 Caris Life Sciences
12.2.7.1 Company Overview
12.2.7.2 Product Portfolio
12.2.7.3 Demographic Reach and Achievements
12.2.7.4 Certifications
12.2.8 Others
13 Industry Events and Developments
List of Key Figures and Tables
1. Global Cancer/Tumour Profiling Market: Key Industry Highlights, 2016 and 2026
2. Global Cancer/Tumour Profiling Historical Market: Breakup by Cancer Type (USD Billion), 2017-2021
3. Global Cancer/Tumour Profiling Market Forecast: Breakup by Cancer Type (USD Billion), 2022-2027
4. Global Cancer/Tumour Profiling Historical Market: Breakup by Biomarker Type (USD Billion), 2017-2021
5. Global Cancer/Tumour Profiling Market Forecast: Breakup by Biomarker Type (USD Billion), 2022-2027
6. Global Cancer/Tumour Profiling Historical Market: Breakup by Technology (USD Billion), 2017-2021
7. Global Cancer/Tumour Profiling Market Forecast: Breakup by Technology (USD Billion), 2022-2027
8. Global Cancer/Tumour Profiling Historical Market: Breakup by Application (USD Billion), 2017-2021
9. Global Cancer/Tumour Profiling Market Forecast: Breakup by Application (USD Billion), 2022-2027
10. Global Cancer/Tumour Profiling Historical Market: Breakup by Region (USD Billion), 2017-2021
11. Global Cancer/Tumour Profiling Market Forecast: Breakup by Region (USD Billion), 2022-2027
12. North America Cancer/Tumour Profiling Historical Market: Breakup by Country (USD Billion), 2017-2021
13. North America Cancer/Tumour Profiling Market Forecast: Breakup by Country (USD Billion), 2022-2027
14. Europe Cancer/Tumour Profiling Historical Market: Breakup by Country (USD Billion), 2017-2021
15. Europe Cancer/Tumour Profiling Market Forecast: Breakup by Country (USD Billion), 2022-2027
16. Asia Pacific Cancer/Tumour Profiling Historical Market: Breakup by Country (USD Billion), 2017-2021
17. Asia Pacific Cancer/Tumour Profiling Market Forecast: Breakup by Country (USD Billion), 2022-2027
18. Latin America Cancer/Tumour Profiling Historical Market: Breakup by Country (USD Billion), 2017-2021
19. Latin America Cancer/Tumour Profiling Market Forecast: Breakup by Country (USD Billion), 2022-2027
20. Middle East and Africa Cancer/Tumour Profiling Historical Market: Breakup by Country (USD Billion), 2017-2021
21. Middle East and Africa Cancer/Tumour Profiling Market Forecast: Breakup by Country (USD Billion), 2022-2027
22. Global Cancer/Tumour Profiling Market Structure
Key Questions Answered in the Report
In 2020, the global cancer/tumour profiling market attained a value of nearly USD 7.8 billion.
The market is projected to grow at a CAGR of 10.2% between 2022 and 2027.
The industry is being driven by the rising global incidences of cancer and the expanding usage of biomarkers in identifying the formation of tumours.
The key trends augmenting the market expansion in the forecast period are the increasing funding for activities aimed at improving the overall course of disease diagnosis and treatment, technological advancements in tumour profiling, and the increasing demand for individualised pharmaceutical products.
The major regions in the industry are North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
The various cancer types in the industry are breast cancer, lung cancer, colorectal cancer, prostate cancer, and melanoma, among others.
The major biomarker types of cancer/tumour profiling are genetic biomarkers and protein biomarkers, among others.
The significant technologies of cancer/tumour profiling in the market are immunoassays, next-generation sequencing, polymerase chain reaction, in situ hybridisation, microarrays, and mass spectrometry, among others.
The several applications of cancer/tumour profiling in the market are research applications and clinical applications.
The major players in the industry are Illumina, Inc., Qiagen N.V., NeoGenomics Laboratories, Inc., Sysmex Corporation, HTG Molecular Diagnostics, Inc., Helomics Corporation, and Caris Life Sciences, among others.
Analyst Review
The global cancer/tumour profiling market attained a value of about USD 7.8 billion in 2020, driven by the rising global incidences of cancer. Aided by technological advancements in tumour profiling, the market is expected to witness a further growth in the forecast period of 2022-2027, growing at a CAGR of 10.2%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its cancer types, the cancer/tumour profiling industry can be segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, and melanoma, among others. By biomarker types, the industry can be divided into genetic biomarkers and protein biomarkers, among others. On the basis of technology, the market is classified into immunoassays, next-generation sequencing, polymerase chain reaction, in situ hybridisation, microarrays, and mass spectrometry, among others. Based on application, the industry is bifurcated into research activities and clinical applications. The major regional markets for cancer/tumour profiling are North America, Latin America, Europe, the Middle East and Africa, the Asia Pacific. The key players in the above market include Illumina, Inc., Qiagen N.V., NeoGenomics Laboratories, Inc., Sysmex Corporation, HTG Molecular Diagnostics, Inc., Helomics Corporation, and Caris Life Sciences, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER